Efficacy results from a phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors.
P. J. Woll
Other Remuneration - Support for conference attendance
K. N. Moore
No relevant relationships to disclose
S. Bhatia
Research Funding - Immunogen
F. V. Fossella
Research Funding - Immunogen
L. C. Chen
No relevant relationships to disclose
M. O'Brien
No relevant relationships to disclose
P. Lorigan
No relevant relationships to disclose
S. D. Weitman
Consultant or Advisory Role - Immunogen
J. J. O'Leary
Employment or Leadership Position - Immunogen
Stock Ownership - Immunogen
S. Zildjian
Employment or Leadership Position - Immunogen
E. Bulger
Employment or Leadership Position - Immunogen
R. Guild
Employment or Leadership Position - Immunogen
M. H. Shah
Research Funding - Immunogen